Clinical Report: FDA Drops Warning From GLP-1 RAs

Overview

The FDA has removed warnings regarding suicidal ideation and behavior from GLP-1 receptor agonists following a comprehensive analysis of clinical data. This decision is based on findings from 91 placebo-controlled trials involving over 107,910 patients, which showed no increased risk of psychiatric adverse events.

Background

The safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has been a concern due to initial warnings related to suicidal ideation based on older weight loss medications. These medications are now widely used for weight management and glycemic control in patients with obesity and type 2 diabetes. The FDA's recent review aims to align safety messaging across all GLP-1 RA products and reassure healthcare providers and patients about their safety.

Data Highlights

The FDA's analysis included:

• 91 placebo-controlled trials
• 107,910 patients
• No increased risk of suicidal ideation or behavior
• No increased risk of other psychiatric adverse events

Key Findings

• The FDA found no signal for suicidal ideation or self-harm in GLP-1 RA users.
• Labeling updates will apply to Saxenda, Wegovy, and Zepbound.
• The initial review in January 2024 did not identify an association but was limited by a small number of reported events.
• A large retrospective cohort study showed no increased risk of intentional self-harm among GLP-1 RA users compared to SGLT2 inhibitors.
• Patients should continue GLP-1 RA medications as prescribed.
• Healthcare providers are encouraged to discuss these findings with patients.

Clinical Implications

Healthcare providers should feel reassured about the safety of GLP-1 RAs concerning suicidal ideation and behavior. It is crucial to continue monitoring patients for any mental health concerns and refer them for evaluation if necessary.

Conclusion

The FDA's decision to remove warnings from GLP-1 RAs reflects a thorough review of safety data, reinforcing the medications' role in managing obesity and type 2 diabetes without the associated psychiatric risks previously indicated.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
2. American College of Cardiology, Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity, 2023 -- SELECT Trial
3. PMC, Summary of Revisions: Standards of Care in Diabetes—2026, 2026 -- ADA Standards
4. retinal physician — The Effect of GLP-1RAs in Diabetic Retinopathy
5. The New Gastroenterologist — Recent Findings Link GLP-1 Receptor Agonists to Increased Risk of GERD
6. The New Gastroenterologist — Key Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists: What Prescribers Need to Consider
7. conexiant — GLP-1 Drugs Linked to GI Effects, Uncertain Signals
8. The Effect of GLP-1RAs in Diabetic Retinopathy
9. Recent Findings Link GLP-1 Receptor Agonists to Increased Risk of GERD
10. Key Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists: What Prescribers Need to Consider
11. GLP-1 Drugs Linked to GI Effects, Uncertain Signals
12. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications | FDA
13. Summary of Revisions: Standards of Care in Diabetes—2026 - PMC
14. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity - American College of Cardiology